Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Feb;9(2):320-3.
doi: 10.3748/wjg.v9.i2.320.

Effect of leflunomide on immunological liver injury in mice

Affiliations

Effect of leflunomide on immunological liver injury in mice

Hong-Wei Yao et al. World J Gastroenterol. 2003 Feb.

Abstract

Aim: To study the effect of leflunomide on immunological liver injury (ILI) in mice.

Methods: ILI was induced by tail vein injection of 2.5 mg Bacillus Calmette-Guerin (BCG), and 10 d later with 10 microg lipopolysaccharide (LPS) in 0.2 mL saline (BCG+LPS). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), nitric oxide (NO) level in plasma and molondiadehyde (MDA), glutathione peroxidase (GSHpx) in liver homogenate were assayed by spectroscopy. The serum content of tumor necrosis factors-alpha (TNF-alpha) was determined by ELISA. Interleukin-1 (IL-1), interleukin-2 (IL-2) and Concanavalin A (ConA)-induced splenocyte proliferation response were determined by methods of (3)H-infiltrated cell proliferation.

Results: Leflunomide (4, 12, 36 mg.kg(-1)) was found to significantly decrease the serum transaminase (ALT, AST) activity and MDA content in liver homogenate, and improve reduced GSHpx level of liver homogenate. Leflunomide (4, 12, 36 mg.kg(-1)) significantly lowered TNF-alpha and NO level in serum, and IL-1 produced by intraperitoneal macrophages(PMphi). Moreover, the decreased IL-2 production and ConA-induced splenocyte proliferation response were further inhibited.

Conclusion: These findings suggested that leflunomide had significant protective action on ILI in mice.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci. 2002;323:190–193. - PubMed
    1. Wendling D. [Leflunomide in the treatment of rheumatoid arthritis] Ann Med Interne (Paris) 2002;153:21–24. - PubMed
    1. Alldred A, Emery P. Leflunomide: A novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2001;2:125–137. - PubMed
    1. Jakez-Ocampo J, Richaud-Patin Y, Simón JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: An open pilot comparative study. Joint Bone Spine. 2002;69:307–311. - PubMed
    1. Williams JW, Mital D, Chong A, Kottayil A, Millis M, Longstreth J, Huang W, Brady L, Jensik S. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73:358–366. - PubMed

Publication types